Research and Markets: 2015 Investigation Report on China’s Voriconazole (Pfizer) Market
September 3, 2015 | By Business Wire News
DUBLIN
Research and Markets (http://www.researchandmarkets.com/research/6vzlb2/investigation) has announced the addition of the “Investigation Report on China Voriconazole Market, 2010-2019” report to their offering.
In recent years, the abuse of antibiotics has resulted in the mass generation of drug-resistant strains and the increased incidence of fungal infection deep seated in tissues. On the other hand, as the number of patients with immune deficiency increases and people take human organ transplant, interventional treatment and chemotherapeutic agents for tumor, the incidence of fungal infection has gone up gradually, which has boosted the fast growth of anti-fungal drugs.
That the incidence of fungal infection has reached 80% in today’s China has driven the rapid growth of anti-fungal drug market. The overall market scale of domestic anti-fungal infection drugs has hit over CNY 5 billion, of which drugs for deep-seated fungal infection take up over 60%.
Voriconazole, a kind of triazole, was developed by Pfizer and came into the US market in 2002. In 2005, voriconazole was introduced into China with Pfizer and its division Upjohn taking up more than 50% of the market. Currently, local firms making voriconazole are Ebang Pharmaceutical, Sichuan Beauty Sport Huakang Pharmaceutical Co., Ltd, Jincheng HEALTH Pharmaceutical Co., Ltd and GeneTech Pharm which occupy the rest Chinese market. According to CRI’s investigation, Voriconazole develops fast after entering China with annual sales rising from CNY 1.14 million in 2005 to CNY 963 million in 2014 and CAGR reaching up to 439.11%.
According to the social epidemiological study, fungal infection is a disease featuring relatively high incidence and reinfection rate. Therefore, anti-fungal drugs enjoy good market prospects.
Key Topics Covered:
1 Related Concepts of Voriconazole
2 Market Profile of Voriconazole in China
3 Survey on Sales Status of Voriconazole in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Voriconazole in China, 2010-2014
5 Survey on Dosage Forms of Voriconazole in China, 2010-2014
6 Reference Price of Voriconazole in Chinese Hospitals in 2014
7 Major Manufacturers of Voriconazole in the Chinese Market, 2010-2014
8 Market Outlook of Voriconazole in China, 2015-2019
Companies Mentioned
– Ebang Pharmaceutical
– GeneTech Pharm
– Jincheng HEALTH Pharmaceutical Co., Ltd
– Pfizer
– Sichuan Beauty Sport Huakang Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/6vzlb2/investigation
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903005606/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Agrochemicals and Fertilisers
